646 related articles for article (PubMed ID: 14717619)
21. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
22. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
23. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C; Sorbara F; Perrin E
Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
[TBL] [Abstract][Full Text] [Related]
24. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
28. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
Asherson P; Bushe C; Saylor K; Tanaka Y; Deberdt W; Upadhyaya H
J Psychopharmacol; 2014 Sep; 28(9):837-46. PubMed ID: 25035246
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Heiligenstein JH; Faries DE; Galil N; Dittmann R; Emslie GJ; Kratochvil CJ; Laws HF; Schuh KJ;
Pediatrics; 2002 Dec; 110(6):e75. PubMed ID: 12456942
[TBL] [Abstract][Full Text] [Related]
31. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
[TBL] [Abstract][Full Text] [Related]
32. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Walker DJ; Mason O; Clemow DB; Day KA
Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
[TBL] [Abstract][Full Text] [Related]
33. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.
Sobanski E; Sabljic D; Alm B; Baehr C; Dittmann RW; Skopp G; Strohbeck-Kuehner P
Pharmacopsychiatry; 2012 May; 45(3):100-7. PubMed ID: 22174029
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
35. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.
Robison RJ; Reimherr FW; Marchant BK; Faraone SV; Adler LA; West SA
J Clin Psychiatry; 2008 Feb; 69(2):213-21. PubMed ID: 18211131
[TBL] [Abstract][Full Text] [Related]
36. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
37. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD.
Sutherland SM; Adler LA; Chen C; Smith MD; Feltner DE
J Clin Psychiatry; 2012 Apr; 73(4):445-50. PubMed ID: 22313788
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder.
Hirata Y; Goto T; Takita Y; Trzepacz PT; Allen AJ; Ichikawa H; Takahashi M
Asia Pac Psychiatry; 2014 Sep; 6(3):292-301. PubMed ID: 24376099
[TBL] [Abstract][Full Text] [Related]
39. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
40. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Prasad S; Steer C
Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
